Skip to main content

Table 2 In vitro parameters of GC sensitivity and relative decrease in DAS

From: In vitro glucocorticoid sensitivity is associated with clinical glucocorticoid therapy outcome in rheumatoid arthritis

Bioassays GC binding assay
  β (95% CI)a P value   β (95% CI)a P value
IL-2-EC50 -0.014 (-0.028-0.001) 0.058 KD 0.03 (0.014-0.046) 0.001
Age 0.005 (-0.002-0.110) 0.161 Age 0.009 (0.002-0.017) 0.020
Gender 0.128 (-0.057-0.312) 0.169 Gender 0.199 (0.013-0.385) 0.037
Use of NSAID 0.087 (-0.087-0.261) 0.316 Use of NSAID 0.212 (0.025-0.400) 0.028
Number of DMARDs 0.023 (-0.079-0.125) 0.647 Number of DMARDs 0.112 (0.004-0.221) 0.043
Use of anti-TNF-α 0.008 (-0.283-0.299) 0.955 Use of anti-TNF-α 0.222 (-0.010-0.455) 0.060
GILZ-EC50 -0.023 (-0.046-0.001) 0.062 GR number/1,000 0.027 (0.012-0.042) 0.001
Age 0.006 (-0.001-0.014) 0.079 Age 0.010 (0.002-0.018) 0.015
Gender 0.116 (-0.075-0.308) 0.225 Gender 0.017 (-0.188-0.223) 0.862
Use of NSAID 0.181 (-0.004-0.366) 0.055 Use of NSAID 0.203 (0.006-0.400) 0.044
Number of DMARDs 0.021 (-0.085-0.126) 0.695 Number of DMARDs 0.084 (-0.027-0.195) 0.132
Use of anti-TNF-α 0.023 (-0.270-0.320) 0.874 Use of anti-TNF-α 0.129 (-0.121-0.378) 0.297
  1. In all four models, relative decrease in DAS was the dependent variable. The data represent the combined bioassays from intramuscularly treated patients with early (n = 14) and established RA (n = 31). GILZ-EC50 and IL-2-EC50 were not associated with relative decrease in DAS in orally treated patients in recent-onset RA (n = 22). The GC-binding assay is performed only in established RA (n = 30, all intramuscular GC). aValues represent adjusted β-coefficients and 95% confidence intervals.